EUVIMEDSkopri EUVIMED
Multizentrische Studie

Donor‐Derived Cell‐Free DNA for Diagnosing Subclinical Rejection: A Pilot Multicenter Study in Japanese Living‐Donor Kidney Transplantation

Toshihito Hirai iD, Taro Banno, Kazuya Omoto, Tomokazu Shimizu, Sumi Hidaka iD, Yu Kijima, Miyuki Furusawa, Ayaka Saitoh, Kohei Unagami iD, Masashi Inui, Hideki Ishida, Toshio Takagi

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70221 ↗

At a glance

Multizentrische Studie in Clinical Transplantation, 2025. Written by Toshihito Hirai and 11 co-authors. Institution: Department of Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan. Major MEDLINE topics: Kidney Transplantation, Living Donors, Graft Rejection, Cell-Free Nucleic Acids. Cited 7 times so far (Crossref); 32 references. Funded by: JSPS KAKENHI, Japan Society for the Promotion of Science.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Donor‐derived cell‐free DNA (dd‐cfDNA) offers a non‐invasive biomarker for detecting allograft injury. However, its performance in predominantly living‐donor transplant settings in Asian populations remains underexplored.

Methods

In a multicenter prospective pilot study, 73 living‐donor kidney transplant (LKT) recipients from Japan underwent plasma dd‐cfDNA testing and protocol biopsies approximately 1 year post‐transplant. Diagnostic performance of dd‐cfDNA for subclinical antibody‐mediated rejection (AMR) was evaluated at 1.0% and 0.5% cut‐off thresholds.

Results

Eight patients (11.0%) were diagnosed with subclinical active AMR. Patients with dd‐cfDNA ≥1.0% showed significantly higher incidence of AMR compared to those with dd‐cfDNA

Subjects

MeSH terms (MEDLINE)

Kidney TransplantationLiving DonorsGraft RejectionCell-Free Nucleic AcidsBiomarkersKidney Failure, ChronicHumansPilot ProjectsMaleFemaleMiddle AgedProspective StudiesFollow-Up StudiesPrognosisAdultGraft SurvivalJapanGlomerular Filtration RateRisk FactorsIsoantibodiesAgedEast Asian People

Author keywords

biomarkerdonor‐derived cell‐free DNAdonor‐specific antibodysubclinical antibody‐mediated rejectionsurveillance biopsy

Substances

Cell-Free Nucleic AcidsBiomarkersIsoantibodies

Authors and institutions

  • Department of Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan.
  • Yocho-machi Clinic, Tokyo, Japan.
  • Department of Organ Transplant Medicine, Tokyo Women's Medical University Hospital, Tokyo, Japan.
  • Department of Urology, Toda Central General Hospital, Saitama, Japan.
  • Department of Nephrology, Shonan Kamakura General Hospital, Kamakura, Japan.
  • Department of Urology, Yachiyo Medical Center, Tokyo Women's Medical University, Chiba, Japan.

ORCID profiles: Toshihito Hirai, Sumi Hidaka, Kohei Unagami

Funding

  • JSPS KAKENHI
  • Japan Society for the Promotion of Science

Cite

APA

Hirai, T., Banno, T., Omoto, K., Shimizu, T., Hidaka, S., Kijima, Y., Furusawa, M., Saitoh, A., Unagami, K., Inui, M., Ishida, H., & Takagi, T. (2025). Donor‐Derived Cell‐Free DNA for Diagnosing Subclinical Rejection: A Pilot Multicenter Study in Japanese Living‐Donor Kidney Transplantation. Clinical Transplantation. https://doi.org/10.1111/ctr.70221

Vancouver

Hirai T, Banno T, Omoto K, Shimizu T, Hidaka S, Kijima Y, et al. Donor‐Derived Cell‐Free DNA for Diagnosing Subclinical Rejection: A Pilot Multicenter Study in Japanese Living‐Donor Kidney Transplantation. Clinical Transplantation. 2025. doi:10.1111/ctr.70221

BibTeX
@article{Hirai2025,
  author = {Hirai, Toshihito and Banno, Taro and Omoto, Kazuya and Shimizu, Tomokazu and Hidaka, Sumi and Kijima, Yu and Furusawa, Miyuki and Saitoh, Ayaka and Unagami, Kohei and Inui, Masashi and Ishida, Hideki and Takagi, Toshio},
  title = {Donor‐Derived Cell‐Free DNA for Diagnosing Subclinical Rejection: A Pilot Multicenter Study in Japanese Living‐Donor Kidney Transplantation},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70221}
}
Start for free →